Overall, our findings on liver carcinogenic and hepatotoxic pathway activation patterns suggest that PFESA-BP2 increases the risk of liver toxicity and HCC development, particularly at low doses. This evidence concerns the gene IGFBP2 and hepatocellular carcinoma.